Thera-SAbDab

ANETUMAB

> Structural Summary

Therapeutic	Anetumab
Target	MSLN
Heavy Chain	QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
Light Chain	DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb ADC
Isotype	G1
Highest Clinical Trial (August '23)	Phase-II
Estimated Status (August '23)	Active
Recorded Developmental Technology	MorphoSys HuCAL Phage Display
INN Year Proposed	2013
INN Year Recommended	2014
Companies Involved	Bayer HealthCare%3BImmunoGen%3BMorphoSys%3BNational Cancer Institute %28USA%29
Conditions Approved	na
Conditions Active	Lung cancer%3BMesothelioma%3BOvarian cancer%3BPancreatic cancer%3BSolid tumours%3BNon-small cell lung cancer%3BMalignant thymoma
Conditions Discontinued	Fallopian tube cancer%3BPeritoneal cancer
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy